


## St John's DermAcademy Podcasts by Dr Sarah Drummond

### Episode 14: Immunobullous disorders - Part 1: Bullous pemphigoid



Dr Thomas Tull  
BSc (hons), MBBS, PhD, MRCP (UK)

Consultant Dermatologist, St John's Institute of Dermatology  
Guy's and St Thomas' NHS Foundation Trust

#### In this episode we discuss...

- The clinical features and risk factors for developing bullous pemphigoid
- How to differentiate bullous pemphigoid from other subepidermal blistering disorders
- Management of bullous pemphigoid including:
  - Preferred first and second line agents
  - How and when to reduce treatment
  - What to do in severe and refractory cases

#### Resources and further reading:

- European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated)  
(<https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220>)
- British Association of Dermatologists' guidelines for the management of bullous pemphigoid, 2012  
(<https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072>)

**Disclosure:** Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.